Home LiteratureArticle Details
PMID: 7621813 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Molecular evolution of plasminogen activator inhibitor-1 functional stability.

The EMBO journal ·Vol. 14 ·No. 13 ·1995-07-03 ·Pages 2969-77

Berkenpas MB, Lawrence DA, Ginsburg D

Abstract

Plasminogen activator inhibitor-1 (PAI-1) is a member of the serine protease inhibitor (serpin) supergene family and a central regulatory protein in the blood coagulation system. PAI-1 is unique among serpins in exhibiting distinct active and inactive (latent) conformations in vivo. Though the structure of latent PAI-1 was recently solved, the structure of the short-lived, active form of PAI-1 is not known. In order to probe the structural basis for this unique conformational change, a randomly mutated recombinant PAI-1 expression library was constructed in bacteriophage and screened for increased functional stability. Fourteen unique clones were selected, and shown to exhibit functional half-lives (T1/2S) exceeding that of wild-type PAI-1 by up to 72-fold. The most stable variant (T1/2 = 145 h) contained four mutations. Detailed analysis of these four mutations, individually and in combination, demonstrated that the markedly enhanced functional stability of the parent compound mutant required contributions from all four substitutions, with no individual T1/2 exceeding 6.6 h. The functional stability of at least eight of the remaining 13 compound mutants also required interactions between two or more amino acid substitutions, with no single variant increasing the T1/2 by > 10-fold. The nature of the identified mutations implies that the unique instability of the PAI-1 active conformation evolved through global changes in protein packing and suggest a selective advantage for transient inhibitor function.

MeSH Terms
Amino Acid Sequence Binding Sites/genetics Biological Evolution Computer Simulation Enzyme Activation/genetics Enzyme Stability/genetics Models, Molecular Molecular Sequence Data Mutagenesis, Site-Directed Plasminogen Activator Inhibitor 1/chemistry,genetics Point Mutation Protein Conformation
Chemicals
Plasminogen Activator Inhibitor 1
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Berkenpas M B
Howard Hughes Medical Institute, University of Michigan, Ann Arbor 48109-0650, USA.
Lawrence D A
Ginsburg D
References (36)
36 references, click to expand
  1. Tumour biology. Membrane proteases in focus.
    Nature. 1994 Jul 7;370(6484):14-5 PMID: 8015594
  2. The serpin superfamily of proteinase inhibitors: structure, function, and regulation.
    J Biol Chem. 1994 Jun 10;269(23):15957-60 PMID: 8206889
  3. Co-opting a blind watchmaker.
    Science. 1994 Aug 19;265(5175):1032-3 PMID: 7520602
  4. Biological implications of a 3 A structure of dimeric antithrombin.
    Structure. 1994 Apr 15;2(4):257-70 PMID: 8087553
  5. Three novel missense mutations in the antithrombin III (AT3) gene causing recurrent venous thrombosis.
    Hum Genet. 1994 Nov;94(5):509-12 PMID: 7959685
  6. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition.
    J Biol Chem. 1994 Nov 4;269(44):27657-62 PMID: 7961684
  7. A relationship between protein stability and protein function.
    Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):452-6 PMID: 7831309
  8. Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity.
    J Biol Chem. 1995 Apr 21;270(16):9301-6 PMID: 7721851
  9. What do dysfunctional serpins tell us about molecular mobility and disease?
    Nat Struct Biol. 1995 Feb;2(2):96-113 PMID: 7749926
  10. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions.
    Nat Struct Biol. 1994 Jan;1(1):48-54 PMID: 7656006
  11. Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop.
    Nat Struct Biol. 1994 Apr;1(4):251-8 PMID: 7656054
  12. Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function.
    J Mol Biol. 1984 Aug 15;177(3):531-57 PMID: 6332197
  13. Genetic and structural analysis of the protein stability problem.
    Biochemistry. 1987 Nov 3;26(22):6885-8 PMID: 3427049
  14. Hydrophobic stabilization in T4 lysozyme determined directly by multiple substitutions of Ile 3.
    Nature. 1988 Aug 4;334(6181):406-10 PMID: 3405287
  15. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).
    J Biol Chem. 1988 Oct 25;263(30):15454-61 PMID: 2459123
  16. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells.
    Eur J Biochem. 1989 Dec 22;186(3):523-33 PMID: 2514093
  17. Genetic studies of the lac repressor. XIII. Extensive amino acid replacements generated by the use of natural and synthetic nonsense suppressors.
    J Mol Biol. 1990 Mar 20;212(2):295-318 PMID: 2157024
  18. Crystal structure of ovalbumin as a model for the reactive centre of serpins.
    Nature. 1990 Sep 6;347(6288):99-102 PMID: 2395463
  19. Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants.
    J Biol Chem. 1990 Nov 25;265(33):20293-301 PMID: 1700786
  20. Enzyme catalysis: not different, just better.
    Nature. 1991 Mar 14;350(6314):121-4 PMID: 2005961
  21. Global suppression of protein folding defects and inclusion body formation.
    Science. 1991 Jul 5;253(5015):54-8 PMID: 1648264
  22. The plasminogen activator/plasmin system.
    J Clin Invest. 1991 Oct;88(4):1067-72 PMID: 1833420
  23. Mobile reactive centre of serpins and the control of thrombosis.
    Nature. 1991 Oct 10;353(6344):576-8 PMID: 1922367
  24. Structural basis of latency in plasminogen activator inhibitor-1.
    Nature. 1992 Jan 16;355(6357):270-3 PMID: 1731226
  25. Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center.
    J Biol Chem. 1992 Apr 15;267(11):7588-95 PMID: 1559996
  26. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation.
    N Engl J Med. 1992 Dec 10;327(24):1729-33 PMID: 1435917
  27. Randomization of genes by PCR mutagenesis.
    PCR Methods Appl. 1992 Aug;2(1):28-33 PMID: 1490172
  28. Tuning the activity of an enzyme for unusual environments: sequential random mutagenesis of subtilisin E for catalysis in dimethylformamide.
    Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5618-22 PMID: 8516309
  29. Engineering multiple properties of a protein by combinatorial mutagenesis.
    Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8367-71 PMID: 8378307
  30. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.
    J Clin Invest. 1993 Dec;92(6):2756-60 PMID: 8254029
  31. Physiological consequences of loss of plasminogen activator gene function in mice.
    Nature. 1994 Mar 31;368(6470):419-24 PMID: 8133887
  32. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability.
    Biochemistry. 1994 Mar 29;33(12):3643-8 PMID: 8142362
  33. Single amino acid substitutions of alpha 1-antitrypsin that confer enhancement in thermal stability.
    J Biol Chem. 1994 Apr 1;269(13):9627-31 PMID: 8144550
  34. Structural aspects of serpin inhibition.
    FEBS Lett. 1994 May 16;344(2-3):117-24 PMID: 8187869
  35. Localization of vitronectin binding domain in plasminogen activator inhibitor-1.
    J Biol Chem. 1994 May 27;269(21):15223-8 PMID: 7515053
  36. Rapid evolution of a protein in vitro by DNA shuffling.
    Nature. 1994 Aug 4;370(6488):389-91 PMID: 8047147
Article Info
Journal
The EMBO journal
Abbr.
EMBO J
ISSN
0261-4189
Published
1995-07-03
Pages
2969-77
Language
English
Region
England
NLM ID
8208664
PMCID
PMC394356
Subset
IM
Grants
NHLBI NIH HHS · HL49184 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com